Selenium in the Treatment of Arsenic Toxicity and Cancers

PHASE3CompletedINTERVENTIONAL

Enrollment

819

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Arsenical MelanosisArsenical KeratosisArsenical CancersArsenicosisArsenic ExposureArsenic ToxicityArsenic Poisoning

Interventions

DRUG

sodium selenite

200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.

DRUG

placebo

dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast

Trial Locations (1)

SETAC Trial Field Office, Kalibari Town

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

American Cancer Society, Inc.

OTHER

lead

Texas Tech University

OTHER

NCT01442727 - Selenium in the Treatment of Arsenic Toxicity and Cancers | Biotech Hunter | Biotech Hunter